EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1 , an ancillary of JCOG0910

Dai Shida iD, Aya Kuchiba, Tatsuhiro Shibata iD, Tetsuya Hamaguchi, Satoshi Yamasaki, Masaaki Ito, Takaya Kobatake, Toru Tonooka, Tadahiko Masaki, Manabu Shiozawa, Yasumasa Takii, Hiroyuki Uetake und 8 weitere

Cancer Science · 2023

DOI: 10.1111/cas.15834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Dai Shida und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, National Cancer Research and Development Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Large‐scale genomic sequencing of colorectal cancers has been reported mainly for Western populations. Differences by stage and ethnicity in the genomic landscape and their prognostic impact remain poorly understood. We investigated 534 Japanese stage III colorectal cancer samples from the Phase III trial, JCOG0910. Targeted‐capture sequencing of 171 potentially colorectal cancer‐associated genes was performed, and somatic single‐nucleotide variants and insertion–deletions were determined. Hypermutated tumors were defined as tumors with MSIsensor score >7 and ultra‐mutated tumors with POLE mutations. Genes with alterations associated with relapse‐free survival were analyzed using multivariable Cox regression models. In all patients (184 right‐sided, 350 left‐sided), mutation frequencies were TP53 , 75.3%; APC , 75.1%; KRAS , 43.6%; PIK3CA , 19.7%; FBXW7 , 18.5%; SOX9 , 11.8%; COL6A3 , 8.2%; NOTCH3 , 4.5%; NRAS , 4.1%; and RNF43 , 3.7%. Thirty‐one tumors were hypermutated (5.8%; 14.1% right‐sided, 1.4% left‐sided). Modest associations were observed: poorer relapse‐free survival was seen with mutant KRAS (hazard ratio 1.66; p = 0.011) and mutant RNF43 (2.17; p = 0.055), whereas better relapse‐free survival was seen with mutant COL6A3 (0.35; p = 0.040) and mutant NOTCH3 (0.18; p = 0.093). Relapse‐free survival tended to be better for hypermutated tumors (0.53; p = 0.229). In conclusion, the overall spectrum of mutations in our Japanese stage III colorectal cancer cohort was similar to that in Western populations, but the frequencies of mutation for TP53 , SOX9 , and FBXW7 were higher, and the proportion of hypermutated tumors was lower. Multiple gene mutations appeared to impact relapse‐free survival, suggesting that tumor genomic profiling can support precision medicine for colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Colorectal NeoplasmsHumansPrognosisF-Box-WD Repeat-Containing Protein 7Neoplasm Recurrence, LocalMutationGenomics

Stichwörter der Autor:innen

clinical trialcolorectal cancerethnicitygenomicsprecision medicine

Substanzen

F-Box-WD Repeat-Containing Protein 7Proto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan.
  • Graduate School of Health Innovation, Kanagawa University of Human Services, Kanagawa, Japan.
  • Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.

ORCID-Profile: Dai Shida, Tatsuhiro Shibata, Yoshinori Murakami

Förderung

  • Japan Agency for Medical Research and Development
  • National Cancer Research and Development Funds

Zitieren

APA

Shida, D., Kuchiba, A., Shibata, T., Hamaguchi, T., Yamasaki, S., Ito, M., Kobatake, T., Tonooka, T., Masaki, T., Shiozawa, M., Takii, Y., Uetake, H., Okamura, S., Ojima, H., Kazama, S., Takeyama, H., Kanato, K., Shimada, Y., Murakami, Y., & Kanemitsu, Y. (2023). Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1 , an ancillary of JCOG0910. Cancer Science. https://doi.org/10.1111/cas.15834

Vancouver

Shida D, Kuchiba A, Shibata T, Hamaguchi T, Yamasaki S, Ito M, et al. Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1 , an ancillary of JCOG0910. Cancer Science. 2023. doi:10.1111/cas.15834

BibTeX
@article{Shida2023,
  author = {Shida, Dai and Kuchiba, Aya and Shibata, Tatsuhiro and Hamaguchi, Tetsuya and Yamasaki, Satoshi and Ito, Masaaki and Kobatake, Takaya and Tonooka, Toru and Masaki, Tadahiko and Shiozawa, Manabu and Takii, Yasumasa and Uetake, Hiroyuki and Okamura, Shu and Ojima, Hitoshi and Kazama, Shinsuke and Takeyama, Hiroshi and Kanato, Keisuke and Shimada, Yasuhiro and Murakami, Yoshinori and Kanemitsu, Yukihide},
  title = {Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1 , an ancillary of JCOG0910},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15834}
}
Kostenlos starten →